These findings suggest that TGF-β1 polymorphism and levels are important factors to consider in the development of preventive and treatment strategies for hepatic cirrhosis and hepatitis C. However, this review warrants the fact that further studies are required to understand the potential therapeutic targets for these diseases due to the mixed assessments observed. The gene discussed is TGFB1; the disease is Cirrhosis.